Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
glaxosmithkline
6
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
6
×
new york top stories
novartis
6
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
gene therapy
abbvie
biogen
cancer immunotherapy
clinical trials
fda
immunotherapy
nonalcoholic steatohepatitis
akcea therapeutics
amgen
gilead sciences
What
roundup
bio
news
biotech
cancer
crispr
days
drug
nash
new
remains
abbvie’s
according
acquisitions
ahead
akcea
albert
allogene
approval
august
biggest
biofourmis
biogen’s
biopharmaceutical
bourla
bucks
busy
cases
celebrate
centers
ceo
chance
cigarettes
companies
company
control
convo
corner
day
deaths
Language
unset
unknown
Current search:
novartis
×
" new york blog main "
×
glaxosmithkline
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More